Difference between revisions of "The Future of R&D in Pharmaceutical Industry in 2025"
Ruthdonners (talk | contribs) m |
Ruthdonners (talk | contribs) m |
||
| Line 6: | Line 6: | ||
Eva Stjernschantz<br> | Eva Stjernschantz<br> | ||
<br> | <br> | ||
'''Work under construction. In case you have any questions | '''Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to [mailto:ruthdonners@hotmail.com contact us].''' | ||
<br><br> | <br><br> | ||
==Scenarios.== | ==Scenarios.== | ||
| Line 12: | Line 12: | ||
To be added<br><br> | To be added<br><br> | ||
==Driving forces.== | ==Driving forces.== | ||
''Edited existing ones''<br><br> | '''Edited existing ones'''<br><br> | ||
• [[Increasing potential to grow based on new available technology]]<br> | • [[Increasing potential to grow based on new available technology]]<br> | ||
• [[Struggling old world economy]]<br> | • [[Struggling old world economy]]<br> | ||
| Line 22: | Line 22: | ||
• [[Legal Restrictions for Biotech increasing in certain countries, decreasing in others]]<br> | • [[Legal Restrictions for Biotech increasing in certain countries, decreasing in others]]<br> | ||
<br><br>''two more will be added''<br><br> | <br><br>''two more will be added''<br><br> | ||
''Added new ones''<br><br> | '''Added new ones'''<br><br> | ||
• [[IP rights]]<br> | • [[IP rights]]<br> | ||
• [[Logistics/Distribution]]<br> | • [[Logistics/Distribution]]<br> | ||
Revision as of 17:41, 12 September 2009
EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu
Eva Stjernschantz
Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.
Scenarios.
To be added
Driving forces.
Edited existing ones
• Increasing potential to grow based on new available technology
• Struggling old world economy
• Increasing Empowerment of Consumers in Healthcare System
• Continuously growing demand for new medical applications
• The increasing gap between developed, emerging and poor economies
• The increasing globalization of markets
• Power of the United Nations
• Legal Restrictions for Biotech increasing in certain countries, decreasing in others
two more will be added
Added new ones
• IP rights
• Logistics/Distribution
• Illnesses of global importance/Pandemics
• Research budget in pharmaceutical industry
• Effect of development of health care system in emerging market countries to existing pharmaceutical industry
• Unification of regulatory approval
• Competitiveness through innovation in biotechnology
• New business models for pharmaceutical industry
two more will be added